Sir: In recent years, several studies reported an increased
rate of cerebrovascular events in patients treated with risperidone.
In April 2005, the U.S. Food and Drug Administration issued
a health advisory warning concerning an increased risk of
death among patients with dementia who were treated with
atypical antipsychotic agents.

Risperidone is a second-generation antipsychotic agent that
reportedly increases the blood level of glucose and alters
changes in lipid profiles.